Galectin Therapeutics Hits New 52-Week Low at $5.06 (GALT)
Galectin Therapeutics (NASDAQ:GALT) reached a new 52-week low during trading on Friday , AnalystRatings.NET reports. The stock traded as low as $5.06 and last traded at $5.20, with a volume of 465,666 shares trading hands. The stock had previously closed at $5.47.
Several analysts have recently commented on the stock. Analysts at Aegis downgraded shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 1st. Separately, analysts at BMO Capital Markets reiterated a “positive” rating on shares of Galectin Therapeutics in a research note on Tuesday, July 29th. Finally, analysts at MLV & Co
cut their price target on shares of Galectin Therapeutics from $27.00 to $15.00 in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock.
The stock’s 50-day moving average is $11. and its 200-day moving average is $13.03. The company’s market cap is $114.4 million.
Galectin Therapeutics (NASDAQ:GALT) last released its earnings data on Thursday, August 7th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.21) by $0.04. Analysts expect that Galectin Therapeutics will post $-0.93 EPS for the current fiscal year.
Galectin Therapeutics Inc (NASDAQ:GALT) is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.